Accordingly, we comprehensively analyzed the TGF-β1 mRNA levels in different etiologies of CLDs and observed that TGF-β1 was higher in patients with CHB, AIH, NASH and cirrhosis, compared to healthy controls (Figures 5A-D). Here, TGFB1 is linked to metabolic dysfunction-associated steatohepatitis.